VistaGen Therapeutics Company Presentation

: VTGN ƒ Oral prodrug of 7-Cl-KYNA, a potent and selective NMDAR glycine site antagonist ƒ Exceptional safety in all studies to date ƒ Recent positive preclinical data show increased brain concentrations of 7-Cl-KYNA when administered in combination with FDA-approved probenecid ƒ Assessing multiple go forward opportunities ƒ FDA Fast Track designations in MDD and pain AV-101 (4-Cl- KYN)